Zhejiang CONBA Pharmaceutical Co.,Ltd.

SHSE:600572 Rapport sur les actions

Capitalisation boursière : CN¥11.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zhejiang CONBA PharmaceuticalLtd Résultats passés

Passé contrôle des critères 2/6

Zhejiang CONBA PharmaceuticalLtd has been growing earnings at an average annual rate of 23.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.6% per year. Zhejiang CONBA PharmaceuticalLtd's return on equity is 7.8%, and it has net margins of 8.1%.

Informations clés

23.4%

Taux de croissance des bénéfices

23.4%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie10.9%
Taux de croissance des recettes-0.6%
Rendement des fonds propres7.8%
Marge nette8.1%
Prochaine mise à jour des résultats24 Aug 2024

Mises à jour récentes des performances passées

Recent updates

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21
Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Ventilation des recettes et des dépenses

Comment Zhejiang CONBA PharmaceuticalLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

SHSE:600572 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Mar 246,4265232,590314
31 Dec 236,7335922,833298
30 Sep 236,6967522,869217
30 Jun 236,6846622,905194
31 Mar 236,4305392,803194
31 Dec 226,0003582,582196
30 Sep 226,1412,0272,690207
30 Jun 226,5301,9842,825214
31 Mar 226,6782,0732,945210
31 Dec 216,5682,0173,001202
30 Sep 216,2821292,974196
30 Jun 215,8342152,907190
31 Mar 215,8213192,887184
31 Dec 205,9094532,979185
30 Sep 205,918-2763,062182
30 Jun 206,313-2523,335171
31 Mar 206,707-3423,753182
31 Dec 196,768-3463,844183
30 Sep 196,8555153,985201
30 Jun 196,9786524,025202
31 Mar 196,9757263,945191
31 Dec 187,0188153,954185
30 Sep 187,0678793,896167
30 Jun 186,6448803,589225
31 Mar 185,9797903,163185
31 Dec 175,2947112,655151
30 Sep 175,2665982,39696
30 Jun 175,3115192,2100
31 Mar 175,6404772,1120
31 Dec 166,0204412,1000
30 Sep 166,0922751,9830
30 Jun 166,1413081,9520
31 Mar 165,8824681,8970
31 Dec 155,3024401,8570
30 Sep 154,7587701,8990
30 Jun 154,1147041,8450
31 Mar 153,7465391,8100
31 Dec 143,5825521,7600
30 Sep 143,3985091,6440
30 Jun 143,2124991,6070
31 Mar 142,9854511,5370
31 Dec 132,9244171,5080
30 Sep 132,8244071,4770

Des revenus de qualité: 600572 has high quality earnings.

Augmentation de la marge bénéficiaire: 600572's current net profit margins (8.1%) are lower than last year (8.4%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 600572's earnings have grown significantly by 23.4% per year over the past 5 years.

Accélération de la croissance: 600572's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 600572 had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).

Rendement des fonds propres

ROE élevé: 600572's Return on Equity (7.8%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y